These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 35669769)

  • 1. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
    Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():849468. PubMed ID: 35669769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():831848. PubMed ID: 35320931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognostic model based on CLEC6A predicts clinical outcome of breast cancer patients.
    Chen L; Dhoomun DK; Liu Q; Kong X; Li X; Peng S; Lan P; Wang J
    Int Immunopharmacol; 2024 Aug; 137():112411. PubMed ID: 38852520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
    Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
    [No Abstract]   [Full Text] [Related]  

  • 5. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator.
    Chen L; Bai P; Kong X; Huang S; Wang Z; Wang X; Fang Y; Wang J
    Front Cell Dev Biol; 2021; 9():656741. PubMed ID: 33859986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
    Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
    Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram.
    Jia Z; Xing H; Wang J; Wang X; Wang X; Liu C; He J; Wu S; Miao J; Liu H; Liu Y
    Pathol Res Pract; 2024 Sep; 261():155504. PubMed ID: 39116570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated oxidative stress score for predicting prognosis in stage III gastric cancer undergoing surgery.
    Liu YH; Meng R; Zhu B; Zhan QQ; Yang X; Ding GY; Jia CL; Liu QY; Xu WG
    Pathol Oncol Res; 2023; 29():1610897. PubMed ID: 37334172
    [No Abstract]   [Full Text] [Related]  

  • 11. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.
    Qin T; Zeng YD; Qin G; Xu F; Lu JB; Fang WF; Xue C; Zhan JH; Zhang XK; Zheng QF; Peng RJ; Yuan ZY; Zhang L; Wang SS
    Oncotarget; 2015 Oct; 6(32):33972-81. PubMed ID: 26378017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
    AiErken N; Shi HJ; Zhou Y; Shao N; Zhang J; Shi Y; Yuan ZY; Lin Y
    Int J Biol Sci; 2017; 13(9):1172-1179. PubMed ID: 29104508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDL1-Based Nomogram May Be of Potential Clinical Utility for Predicting Survival Outcome in Stage III Breast Cancer.
    Zhang X; Li R; Wang G
    Breast Cancer (Dove Med Press); 2023; 15():731-746. PubMed ID: 37905205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    Cancer Manag Res; 2020; 12():1543-1567. PubMed ID: 32184659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: A prognostic nomogram study.
    Zheng Y; Wu C; Yan H; Chen S
    Clin Chim Acta; 2020 Jul; 506():110-121. PubMed ID: 32156604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer.
    Li C; Ma RZ; Han GY; Guo YH; Zhang YN; Zhang YT; Wang H; Zhang YP; Chen FM; Zhang SG; Wang MC; Hao FR; Zhang YX
    Oncol Res Treat; 2020; 43(11):573-583. PubMed ID: 32957100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
    Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
    [No Abstract]   [Full Text] [Related]  

  • 20. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
    Zhu M; Liang C; Zhang F; Zhu L; Chen D
    Front Oncol; 2021; 11():690336. PubMed ID: 34745934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.